Paradigm Biopharmaceuticals Limited EBIT

The latest EBIT for PBIGF is $-86M as of June 2026. That compares with $-120M in the prior-year period — up 30.4% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Paradigm Biopharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, PBIGF's EBIT moved from $-120M to $-86M — a 30.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Paradigm Biopharmaceuticals Limited's operating scale or balance-sheet position.

Against Healthcare companies, PBIGF currently prints $-86M for EBIT, while the sector average sits near $130B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Paradigm Biopharmaceuticals Limited's growth, margins, and balance sheet.

A EBIT figure of $-86M for PBIGF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting PBIGF's EBIT ($-86M), review year-over-year change from $-120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.